Annual report pursuant to Section 13 and 15(d)

SEGMENT REPORTING

v3.22.1
SEGMENT REPORTING
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]

NOTE 12 – SEGMENT REPORTING

 

In accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable segments: BioSig Technologies, Inc. (parent), NeuroClear Technologies, Inc. and ViralClear Pharmaceuticals, Inc.

 

Information concerning the operations of the Company’s reportable segments is as follows:

 

   

2021

    

2020

  

Revenues (from external customers)

                

BioSig

   $ 441     $ -  

ViralClear

     -       -  

NeuroClear

     -       -  
    $ 441     $ -  
                 

Operating Expenses

                

BioSig

   $ 30,016     $ 30,756  

ViralClear

     3,630       28,387  

NeuroClear

     7       41  
    $ 33,653     $ 59,184  
                 

Income (loss) from operations

                

BioSig

   $ (29,772 )   $ (30,727 )

ViralClear

     (3,077 )     (28,372 )

NeuroClear

     (7 )     (41 )
    $ (32,856 )   $ (59,140 )
                 

Total Assets

                

BioSig

   $ 13,595     $ 24,764  

ViralClear

     1,924       5,622  

NeuroClear

     -       -  
    $ 15,519     $ 30,386